PMID: 7539147May 23, 1995Paper

Evidence for a role of endothelin 1 and protein kinase C in nitroglycerin tolerance

Proceedings of the National Academy of Sciences of the United States of America
T MünzelD G Harrison

Abstract

We sought to examine mechanisms responsible for increased vasoconstriction that occurs during development of nitroglycerin tolerance. Rabbits were treated for 3 days with nitroglycerin patches (0.4 mg/hr), and their aortic segments were studied in organ chambers. This treatment resulted in attenuated in vitro relaxations to nitroglycerin and increased contractile sensitivity to angiotensin II, serotonin, phenylephrine, KCl, and a direct activator of protein kinase C, the phorbol ester phorbol 12,13-dibutyrate. The protein kinase C antagonists calphostin C (100 nM) and staurosporine (10 nM) corrected the hypersensitivity to constrictors in tolerant vessels, yet had minimal effects on constrictions in control vessels. Paradoxically, constrictions caused by endothelin 1 were decreased in nitrate-tolerant vessels. Immunocytochemical analysis revealed intense endothelin 1-like and big endothelin 1-like immunoreactivity in the media of nitroglycerin-tolerant but not of control aortas. The enhanced vasoconstriction to angiotensin II, serotonin, KCl, and phenylephrine could be mimicked in normal vessels by addition of subthreshold concentrations of endothelin 1, and this effect was prevented by calphostin C. We propose that increased a...Continue Reading

References

Nov 1, 1992·Hypertension·J E Andrea, M P Walsh
Oct 15, 1991·Biochemical and Biophysical Research Communications·M Feelisch, M Kelm
Apr 15, 1991·Biochemical and Biophysical Research Communications·R F BrunsH Nakano
Oct 13, 1991·The New England Journal of Medicine·A LermanJ C Burnett
Mar 15, 1989·Biochemical and Biophysical Research Communications·E KobayashiT Tamaoki
Jan 1, 1989·Cardiovascular Drugs and Therapy·J O Parker
Sep 24, 1987·The New England Journal of Medicine·M PackerM Yushak
Jul 1, 1993·Canadian Journal of Physiology and Pharmacology·D Henrion, I Laher
Jun 17, 1993·The New England Journal of Medicine·A GiaidD J Stewart

❮ Previous
Next ❯

Citations

Dec 3, 2011·Cardiovascular Drugs and Therapy·Francesco Iachini BellisariiRaffaele De Caterina
Feb 21, 2004·European Journal of Pharmacology·Ivan S de la LandeJohn D Horowitz
May 30, 1996·The American Journal of Cardiology·T MünzelD G Harrison
Jan 25, 2003·Pharmacology, Biochemistry, and Behavior·Edward Y ChaHoward B Gutstein
Aug 10, 2000·Journal of the American College of Cardiology·T MünzelT Meinertz
Dec 29, 2000·Journal of the American College of Cardiology·D Hébert, J Y Lam
Feb 24, 2001·Journal of the American College of Cardiology·E R AzevedoJ D Parker
Oct 5, 2001·Journal of the American College of Cardiology·T Münzel
Oct 5, 2001·Journal of the American College of Cardiology·T GoriJ D Parker
Mar 30, 2002·Journal of the American College of Cardiology·John O ParkerWayne H Kaesemeyer
Dec 19, 1998·Journal of the American College of Cardiology·P R CaramoriJ D Parker
Feb 19, 1998·The New England Journal of Medicine·J D Parker, J O Parker
Jan 22, 1998·Journal of Cardiovascular Pharmacology·B Fink, E Bassenge
Dec 22, 1999·Journal of Cardiovascular Pharmacology·B FinkE Bassenge
Jul 11, 2001·Journal of Cardiovascular Pharmacology·J KählerT Münzel
Sep 24, 2010·American Journal of Therapeutics·Chandrasekar Palaniswamy, Wilbert S Aronow
Sep 1, 1996·British Journal of Pharmacology·W Zierhut, H A Ball
Dec 20, 2002·Canadian Journal of Physiology and Pharmacology·Jodan D RatzBrian M Bennett
Jul 3, 1998·The Journal of Clinical Investigation·E BassengeB Fink
May 27, 2008·Circulation Journal : Official Journal of the Japanese Circulation Society·Hideyuki IkejimaTakashi Akasaka
Oct 20, 2004·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Ken KanamasaUNKNOWN Secondary Prevention Group
Aug 31, 2000·Biochemical and Biophysical Research Communications·W Kielbasa, H L Fung
May 9, 2002·Expert Opinion on Investigational Drugs·Ian L Megson, David J Webb
Aug 12, 2009·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Edzard SchwedhelmKarsten Sydow
Jun 4, 2008·The Journal of Headache and Pain·Ingelise ChristiansenPeer Tfelt-Hansen

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.